USFDA3 Jul 2026, 05:40 pm
Rubicon Research Facility Undergoes US FDA Inspection
AI Summary
Rubicon Research Ltd announced that its manufacturing facility in Pithampur, Madhya Pradesh, underwent an unannounced inspection by the US FDA from June 29 to July 3, 2026. This was the first inspection since the facility's acquisition last year. The inspection resulted in a Form 483 with two procedural observations, not related to data integrity. The company is confident in addressing these observations and expects a successful outcome, reinforcing its quality and compliance standards. Commercial operations at the facility are slated to ramp up from Q1 2027 as per previous guidance.
Key Highlights
- US FDA inspected Rubicon's Pithampur manufacturing facility.
- Two procedural observations were issued on Form 483.
- Observations do not pertain to data integrity.
- Company confident in timely resolution and successful outcome.
- Commercial operations expected from Q1 2027.
Price Impact
More from RUBICON